Introduction
Notch proteins belong to a family of four evolutionarily conserved transmembrane receptors that play a fundamental role in cell fate decisions including cell proliferation, differentiation, and apoptosis. In mammalian cells, there are four Notch receptors (termed Notch-1, -2, -3, and -4) and five ligands (termed Jagged-1, -2, and Deltalike (Dll)-1, -3, and -4). Although similar, the receptors show differences in structure that are likely responsible for their different expression patterns and unique functions. Notch signaling is initiated by receptorligand interactions between neighboring cells resulting in two successive proteolytic cleavages by TACE (TNFa-converting enzyme) and the g-secretase/presenilin complex. This processing results in the release of the intracellular domain (N IC , the functionally active form of Notch), which translocates to the nucleus and binds CBF-1 (also termed CSL or RBP-Jk), a DNA-binding protein. In the absence of N IC , CBF-1 mediates gene repression by binding with the histone-deacetylase complex SMRT/sin3/HDAC-1; however, binding of N IC to CBF-1 displaces the repressor complex and recruits nuclear coactivators such as MAML1 and histone acetyltransferases converting CBF-1 into a transcriptional activator. CBF-1/Notch interactions result in the expression of various target genes including Hes (Hairy/Enhancer of Split), Hey (Hairy/Enhancer of Split related with YRPW (also known as HesR, HRT, HERP, CHF, and gridlock)), NF-kB, and PPAR families of transcription factors, and cell cycle regulators such as p21 CIP1/WAF1 and cyclin D (Rangarajan et al., 2001; Nickoloff et al., 2002; Iso et al., 2003) .
The Hes (including Hes-1) and Hey (including Hey1 and Hey2) family members are transcription factors that are direct downstream targets of Notch activation. Both families share common domains including a basic helix-loop-helix (bHLH) domain, an orange domain, and a tetrapeptide motif, and they function to repress expression of tissue-specific transcriptional activators and ultimately prevent cell differentiation. Interestingly, these proteins have distinct repression mechanisms with Hes interacting with TLE/Groucho through the tetrapeptide motif and Hey engaging the mSin3 complex through the bHLH domain (Iso et al., 2001) . Hes and Hey proteins not only form homodimers, but in cells that express both proteins, Hes and Hey form heterodimers that may extend their individual repression activity.
Given the complexity of the Notch signaling pathway, it is understandably difficult to predict the outcome of Notch activation. Not only are there multiple Notch receptors and ligands (each with a unique expression pattern), but the large number of target genes and potential crosstalk between Notch and other signaling cascades further complicate the system. This is well illustrated by studies showing that N IC -1 functions differently depending on the cell context in which it is expressed. In mesenchymally derived cells, N IC -1 overexpression has been implicated in tumorigenesis, while in keratinocytes, N IC -1 appears to promote differentiation and possibly function as a tumor suppressor (Artavanis-Tsakonas et al., 1999; Mumm and Kopan, 2000; Nicolas et al., 2003) .
Kaposi's sarcoma (KS), the most common neoplasm in AIDS patients, is a virally induced neoplasm that causes significant morbidity and mortality worldwide. Although the KS-associated herpesvirus (KSHV; also known as human herpesvirus 8, HHV-8) has been identified as the likely etiologic agent responsible for KS, it is currently unknown how KSHV infection leads to KS from a pathophysiological perspective. To date, Notch expression has not been studied in KS; however, endothelial cells (ECs), the precursor of KS cells, are known to express Notch-1, -2, and -4 as well as the ligands Jagged-1, -2, and Dll-1, -4 (Uyttendaele et al., 1996; Luo et al., 1997; Leimeister et al., 2000; Shutter et al., 2000; Tsai et al., 2000; Villa et al., 2001 ). In addition, Notch signaling has been shown to be essential for normal vascular development, and targeted disruption of Notch-1, Notch-1/Notch-4, Jagged-1 or Dll-1 in ECs results in the in utero demise of the embryo due to vascular defects and hemorrhage (Hrabe de Angelis et al., 1997; Xue et al., 1999; Huppert et al., 2000) .
In an attempt to better understand KS pathogenesis, we investigated the expression and activation of Notch proteins in KS and examined the effect of two pharmacologically unique g-secretase inhibitors (a tripeptide aldehyde inhibitor (GSI) and a peptidomimetic inhibitor (LY-411,575)) on KS cell survival (Shimazaki et al., 2001; Lanz et al., 2004; Wong et al., 2004) . The results demonstrated elevated levels of both transmembrane and activated Notch-1, -2, and -4 in KS tumor cells in vitro and in vivo compared to normal ECs. Notch transcriptional activity was confirmed using luciferase reporter assays. Finally, GSI and LY-411,575 treatment resulted in apoptosis of KS cells in vitro. GSI also induced apoptosis and tumor regression or stabilization in nude mice bearing tumors of immortalized KS cells. These results suggest that Notch activation may be involved in KS pathogenesis, with important implications for the development of new therapeutic approaches for this neoplasm.
Results

KS tumor cells express activated Notch pathway proteins in vivo
Immunostaining of fresh frozen, cutaneous KS tissue sections (patch (n ¼ 5) or plaque (n ¼ 4) stage lesions) revealed expression of Notch-1, -2, and -4 in KS tumor cells in all specimens (Figure 1 ). Positive staining (ranging from moderate to intense) was localized in both the cytoplasm and nuclear/perinuclear region of the cells, with the latter finding being indicative of Notch activation. To further examine Notch activation, immunostaining was performed for the Notch target proteins, Hes-1 and Hey1. Positive staining for Hes-1 and Hey1 (ranging from modest to intense) was detected in both the cytoplasm and nucleus of the tumor cells in seven of nine lesions (Figure 1 ). Intense Hes-1-positive staining was also seen in an additional paraffinembedded tissue specimen from a nodular stage KS lesion (data not shown). Finally, the Notch ligand, Jagged-1, was also identified on the KS tumor cells in the same seven KS lesions that expressed Hes-1 and Hey1 (Figure 1 ). Interestingly, both of the negative KS lesions were early, patch stage lesions, while all of the plaque stage lesions were positive for Hes-1, Hey1, and Jagged-1 as well as the only late-stage tumor nodule examined. Although definitive conclusions cannot be drawn without analysis of additional samples, the results suggest that Notch activation increases with tumor stage in KS. Immunostaining also demonstrated that the ECs within the KS lesions were frequently positive for the Notch pathway proteins, which was not unexpected in these angiogenic lesions. However, normal human skin showed little to no positive signal in the dermis for activated Notch-1, Notch-2, Hes-1, Hey1, or Jagged-1, although epidermal keratinocytes demonstrated varying levels of positivity providing an internal positive control (Figure 1 and data not shown).
KS tumor cells express activated Notch proteins in vitro
To confirm and extend these results, expression of Notch pathway proteins was examined in KS tumor cells grown in culture. Western blot analysis revealed constitutive activation of Notch-1 in primary KS tumor cells and the immortalized KS cell line, SLK, compared to normal ECs (Figure 2a To further examine in vitro expression of Notch proteins, ECs, primary KS, and SLK cells were cultured on LabTek chamber slides. Immunostaining revealed diffuse, cytoplasmic positive staining for Notch-1, Notch-4, and Hes-1 in ECs with little detectable Notch-2 and Hey1 (Figure 2b) . Occasionally, ECs with nuclear/perinuclear Notch, Hes-1, or Hey1 were noted indicating the presence of activated Notch. This finding was not unexpected in these subconfluent cultures. In contrast, primary KS cells and SLK cells showed intense cytoplasmic staining for Notch-1 and Notch-4 as well as nuclear/perinuclear localization (Figure 2b) . Similarly, Notch-2 and Hey1 were identified in the nuclear/ perinuclear area of the KS cells; however, overall cytoplasmic positivity was less intense. Notch-2 levels appeared even more modest in SLK cells; however, the expression was concentrated in the perinuclear region (Figure 2b ). Notch activation was also indicated in the primary KS tumor cells by nuclear and cytoplasmic expression of Hes-1 and Hey1. Interestingly, Hes-1 appeared to be localized to the nucleoli of the KS cells. Hey1 expression was also localized to the nucleus in SLK cells; however, Hes-1 was predominantly cytoplasmic ( Figure 2b ).
Activated Notch in KS tumor cells is functional
As Notch activation promotes transcription of Hes-1, Hey1, and Hey2, luciferase reporter constructs driven by the promoters of these genes were used to confirm functional activity of Notch in KS cells (Jarriault et al., 1995; Maier and Gessler, 2000; Iso et al., 2002) . Cells transfected with empty vectors (pGL2 or pLuc) showed low baseline luciferase levels ( Figure 3 ). ECs transfected with HesA/B, Hey1, or Hey2 constructs showed detectable luciferase activity, but primary KS tumor cells showed significantly more activity (87-, 98-, and 130-fold increase compared to ECs, respectively; Po0.05; Figure 3 ). SLK cells also showed significant luciferase activity with the Hey1 and Hey2 constructs (69-fold, 143-fold increase compared to ECs, respectively; Po0.05; Figure 3) ; however, there was no difference between SLK cells with the HesA/B construct and the empty vector control. These results indicate that activated Notch is functionally active in both primary and immortalized KS tumor cells.
Notch inhibition results in apoptosis in cultured KS tumor cells
GSI, a pharmacologic agent known to block effectively Notch activation, was used to evaluate the effect of Notch inhibition on KS tumor cells. Initial studies confirmed GSI significantly reduced Notch-1, -2, and -4 activation in ECs and/or SLK cells under our experimental conditions, although Notch activation was retained for a longer time period in the SLK cells ( Figure 4a and data not shown). The different time course of GSI activity may be related to changes in the half-life of N IC , which has been shown to be extended in transformed cells (Weijzen et al., 2002) . GSI treatment also significantly blocked luciferase activity in primary KS cells transfected with the HesA/B, Hey1 or Hey2 reporter constructs (HesA/B: 68% decrease; Hey1: 89% Figure 1 Immunoperoxidase staining for Notch receptors, ligand, and target proteins in KS lesional tissue. KS tumor cells expressed both cytoplasmic and nuclear Notch-1, -2, and -4, a finding indicative of Notch activation. Positive nuclear staining is highlighted in the inset figures within these panels. The tumor cells also expressed cytoplasmic and nuclear Hes-1 and Hey1, two direct downstream targets of Notch activation, and Jagged-1, a Notch ligand. As expected, normal ECs were frequently positive for the Notch pathway proteins in these angiogenic lesions. However, ECs in normal human skin showed little to no positive staining for Notch-1, -2, Hes-1, Hey1, or Jagged-1 (Notch-2 immunostaining is shown as an example). Panels in this figure are from plaque stage KS lesions with the exception of the normal human skin. The red reaction product signifies positive detection of the specified antigen, and staining performed with an isotype control antibody revealed no positive signal. Arrows highlight examples of positive cells c-Secretase inhibitor induces apoptosis in Kaposi's sarcoma CL Curry et al Figure 4b ). Reductions in luciferase were also seen at earlier time points and continued to decrease until the last time point evaluated (data not shown). ECs, primary KS, and SLK cells were treated with GSI for 24 or 48 h and examined for growth arrest and/or apoptosis using DNA/propidium iodide (DNA/PI) staining. While normal confluent ECs (mimicking EC lining the vasculature) were relatively resistant to the effects of GSI (average apoptosis: 11.971.2%; Figure 4c ), primary KS tumor cells underwent apoptosis (average: 35.874.8%) after treatment with GSI ( Figure 4c ). Proliferating ECs, which express modest levels of activated Notch, were not as resistant to GSI and underwent apoptosis as expected (approximately 27% apoptotic; data not shown). Interesting, SLK cells first underwent G 2 /M growth arrest (average: 50.573.7%) when treated with GSI for 48 h; however, apoptosis could be induced if the cells were treated with a second dose of GSI or if they were analysed at 96 h posttreatment (average: 97.871.3%; Figure 4c ). Annexin V staining was used to confirm the results (data not shown).
To confirm that GSI induced growth arrest and/or apoptosis primarily through Notch inhibition, ECs and SLK cells were transduced with a retroviral vector expressing N IC -1, -2, or -4. After demonstrating expression of activated Notch via Western blot and luciferase assays (data not shown), the cells were treated with GSI or DMSO as a control and cell proliferation measured. The effect of GSI on proliferating ECs or SLK cells was abrogated by expression of any of the N IC proteins (Figure 4d and data not shown). Compared to SLK cells transduced with the empty retroviral vector, expression of N IC -1, -2, or -4 in SLK cells resulted in a 2.7-, 3.1-, and 2.3-fold increase in proliferation, respectively, following GSI treatment (Figure 4d ). Similar results were seen in proliferating EC cultures and in studies evaluating DNA/PI staining for both cell types (data not shown).
Although GSI is a potent inhibitor of g-secretase activity, the aldehyde group on this peptide is able to covalently inhibit certain serine proteases. Therefore, similar experiments were performed with LY-411,575, a noncovalent peptidomimetic inhibitor of g-secretase. LY-411,575 has been shown to block g-secretase activity, but no compounds in its class are known to inhibit calpain or other serine proteases. Initial studies confirmed LY-411,575 blocks Notch activation using the luciferase reporter constructs driven by the HesA/B, Hey1 and Hey2 promoters. LY-411,575 did not decrease HesA/B activity (1.1-fold decrease; Figure 5a ), a result that may be related to the overall low HesA/B activity seen in SLK cells in general (Figure 3 ). However, this compound potently blocked Notch activation and significantly reduced luciferase activity with the Hey1 and Hey2 reporter constructs (Hey1: 5.5-fold decrease; Hey2: 13.6-fold decrease; Po0.05; Figure 5a ). With respect to growth arrest/apoptosis, treatment of SLK cells with LY-411,575 induced G 2 /M growth arrest (average: 44.271.8%) compared to control-treated cells (23.870.9%; Po0.05), a result that is consistent with those using GSI (Figure 5b ). LY-411,575, however, had only a modest effect on ECs inducing apoptosis in only 17.471.7% of the cells (Figure 5b ).
Notch inhibition induces apoptosis in immortalized KS tumor cells in vivo
To determine if GSI could also induce apoptosis in an in vivo model system, nude mice were injected with SLK cells intradermally, and palpable tumors formed in 4-6 tumor growth in the GSI-treated versus DMSO-treated and -untreated animals at days 4-7 (Figure 6a ; Po0.05), while DMSO alone had no significant effect on tumor growth at any of the time points. Of the 13 GSI-treated tumors evaluated, two showed tumor regression, two showed stabilization, and the remaining nine tumors demonstrated significantly slower growth than DMSOtreated or -untreated lesions (data not shown). Histologic analysis indicated that GSI induced growth arrest and/or apoptosis in the SLK cells. Hematoxylin and eosin (H&E) staining revealed a large tumor in untreated animals containing actively dividing cells (Figure 6b ). These cells were positive for Ki67, a marker of cell proliferation, while only an occasional cell was positive by TUNEL or activated caspase-3 staining, indicating low levels of apoptosis (7.6% of cells, on average, were activated caspase-3 positive). In contrast, the small GSI-treated tumor contained many cells with enlarged nuclei. These cells showed little evidence of proliferation as seen by the lack of Ki67 positivity, and many of the cells appeared to be apoptotic as indicated by positive TUNEL and activated caspase-3 activity ( Figure 6b ; 40% of cells, on average, were activated caspase-3 positive).
The results showed that two of 13 established SLK cell tumors on the mice regressed in response to GSI treatment. This result was not due to differences in the size of the tumors at treatment initiation (0.18 and 0.49 cm 3 ; tumors ranged from 0.15 to 0.72 cm 3 ), although GSI treatment tended to inhibit tumor growth better in smaller lesions (data not shown). This may be due to better penetration of the compound through the tumor during the intralesional injection. In addition, there was no evidence of systemic spread of the GSI in this experimental system, which may have hampered access of GSI to all of the tumor cells, resulting in the range of results from regression to stabilization to growth inhibition.
Discussion
The pathogenesis of KS is complex and not well understood. In particular, the molecular basis for KS Figure 5 (a) Luciferase activity in SLK cells transfected with HesA/B, Hey1, Hey2, or the empty luciferase reporter constructs (pLuc) as a control. The cells were treated for 24 h with 500 mM LY-411,575 (prepared in DMSO) to block Notch activation or with the same dilution of DMSO as a control. The results showed significant reductions in luciferase activity in cells transfected with the Hey1 (5.5-fold) or Hey2 (13.6-fold) and treated with LY-411,575 compared to the control. However, there was little effect on HesA/B luciferase activity (1.1-fold decrease), which may be related to the overall poor Hes-1 response in these cells. Representative data from one of three independent experiments performed in triplicate are shown. The absorbance value of the DMSO-treated control was set to 100% and the relative reduction in proliferation calculated c-Secretase inhibitor induces apoptosis in Kaposi's sarcoma CL Curry et al tumor cell emergence, survival, and proliferation remains unclear despite active investigation. The current report demonstrates that KS cells both in vitro and in vivo express elevated levels of Notch receptors. In this context, Notch is constitutively activated as demonstrated by expression of Notch target proteins (Hes-1, Hey1) and induction of luciferase expression using reporter constructs driven by Notch-responsive promoters. Moreover, treatment of KS tumor cells with GSI or LY-411,575, two pharmacologically unique compounds that both block Notch activation, results in apoptosis in in vitro and/or in vivo model systems. Given that activated Notch plays a role in cell fate decisions and has been implicated in tumorigenesis, these novel findings may provide important clues to understanding KS pathogenesis and KS tumor cell proliferation.
An oncogenic role for Notch was first identified by Sklar and colleagues in T-cell acute lymphoblastic leukemia (T-ALL) (Ellisen et al., 1991) . Early studies identified a (9 : 7) chromosomal translocation in 10% of T-ALL patients resulting in overexpression of N IC -1 following fusion of the intracellular portion of Notch-1 to the T-cell receptor-b promoter/enhancer. More recently, studies have found as many as 50% of T-ALL patients have other mutations resulting in constitutive Notch-1 activation (Weng et al., 2004) . The activated forms of all four Notch receptors have been implicated in tumorigenesis in a variety of tumors including cervical, head and neck, lung, breast, and pancreatic carcinomas, mesotheliomas, malignant melanomas, and various hematologic malignancies (Gallahan et al., 1996; Girard et al., 1996; Pear et al., 1996; Capobianco et al., 1997; Soriano et al., 2000; Jundt et al., 2002) . Interestingly, the Epstein-Barr virus (EBV) latency protein EBNA-2, which is required for EBV immortalization of B cells, mimics N IC and binds to CBF-1 to recruit transcriptional coactivators and induce gene expression (Hayward, 2004) . However, Notch, like other oncoproteins, is generally not tumorigenic when expressed alone, but instead requires coexpression of additional oncogenic alterations to promote transformation. Studies indicate that N IC -1 can cooperate with c-Myc to induce lymphoid tumors and with ERBB2 to promote mammary tumors (Dievart et al., 1999) . N IC can also cooperate with viral oncogenes. In cervical cancer, which is caused in part by human papilloma Figure 6 (a) Graph of tumor measurements. Established SLK tumors were measured and then directly injected with GSI (48 mg/ dose), DMSO, or left untreated as a control on days 0, 2, 4, and 6. The tumor volume at day 0 was set at 100%, and tumor volume at the subsequent time points was calculated and is presented as a percentage of the original tumor volume. GSI significantly inhibited tumor growth at days 4-7 compared to DMSO or untreated control tumors, while DMSO alone did not have a significant effect on the tumor. The following decreases in tumor volume were seen when comparing GSI to DMSO treatment: Day 2: 42.2%; day 4: 52.7%; day 6: 59.3%; day 7: 49.4%. Results are presented as an average7s.e.m. for a minimum of 13 individual tumors. *Po0.05. (b) Histologic analysis of nude mouse tumors. H&E staining of paraffin-embedded tissue demonstrates a large tumor in the untreated animals containing actively dividing cells (arrow shows a mitotic figure) . Proliferation of these cells was confirmed by positive Ki67 staining and detection of only an occasional cell undergoing apoptosis (TUNEL and activated caspase-3 staining). In contrast, the small GSI-treated tumor contained many cells with enlarged nuclei. Many of these cells appear to undergo apoptosis as indicated by positive activated caspase-3 and TUNEL staining. In addition, the cells showed little evidence of proliferation as seen by the lack of Ki67 positivity c-Secretase inhibitor induces apoptosis in Kaposi's sarcoma CL Curry et al virus (HPV) infection, the HPV oncoproteins E6/E7 perform the critical functions of inactivating p53 and Rb, and activating telomerase. However, E6/E7 expression alone is insufficient to transform human epithelial cells, and Weijzen and co-workers recently demonstrated that N IC -1 coexpression complements E6/E7 activity to fully transform cells (Lathion et al., 2003; Weijzen et al., 2003) . These findings suggest that KSHV infection in KS may be important to constitutive Notch activation in KS tumor cells, and studies are in progress to determine if KSHV infection alters Notch expression and/or activation.
Our results showing GSI induces apoptosis in KS cells are consistent with a recent report demonstrating that GSIs indirectly activate caspase-3 in murine cells, and a study showing induction of apoptosis in melanoma cells (Alves et al., 2004; Qin et al., 2004) . In that study, the investigators (including BJN and LM) found that malignant melanoma cells, which are notoriously resistant to apoptosis, can be effectively killed by GSI through the mitochondrial-based apoptotic pathway. The melanoma cells, but not normal melanocytes, induced expression of several proapoptotic proteins including NOXA, which appeared to mediate cell death. Our studies also showed induction of NOXA in GSItreated SLK cells (unpublished data; CLC, LLR, KEF); however, we found that confluent, but not proliferating ECs were resistant to the effects of GSI. This may be related to the rate of proliferation in our experimental system where confluent ECs are contact inhibited and rarely divide. As ECs lining the normal vasculature in vivo are also growth arrested, these results suggest that GSI treatment would not have a detrimental effect on normal vessels. This conclusion is supported by our animal model data where the mice injected with GSI showed no evidence hemorrhage in or around the tumor. Interestingly, SLK cells initially entered a G 2 / M growth arrest, and did not become apoptotic until 96 h post-treatment. It is possible that the cells initially enter mitotic catastrophe, a form of cell death resulting from aberrant mitosis or re-entry of tumor cells into the cell cycle after prolonged growth arrest (Roninson et al., 2001) . Further studies are needed to confirm or refute this theory.
Although studies have given insight into the apoptotic mechanisms involved in GSI-mediated cell death, it is still unclear how this compound induces apoptosis. gSecretases are known to mediate proteolysis of several transmembrane proteins in addition to Notch including the amyloid b-protein precursor, E-cadherin, and Erb-B4 (Esler et al., 2000; Zhang et al., 2000; Ni et al., 2001; Marambaud et al., 2002) . We have demonstrated inhibition of Notch activation under our experimental conditions and transfection of proliferating ECs and SLK cells with activated Notch proteins rescued the cells from the effects of GSI. Although N IC proteins were unable to completely restore cell proliferation, the results indicate that Notch inhibition by GSI was a key factor responsible for growth inhibition of the cells. In addition, a second compound (LY-411,575) that acts through a different mechanism to inhibit g-secretase also blocked Notch activation in our studies and induced growth arrest in immortalized KS cells. We cannot, however, rule out that a portion of the involved mechanism is through a different signaling pathway. Experiments are in progress using RNA interference to block specifically individual Notch receptors and address this important question. Cancer cells, however, frequently express multiple Notch receptors, and in the case of KS tumor cells, activation of three different Notch receptors was found. Therefore, it may be necessary to simultaneously block multiple Notch receptors in order to kill tumor cells effectively.
In conclusion, this report demonstrates expression of activated Notch in KS tumor cells and shows that this Notch is functionally active. This novel finding adds to our understanding of KS pathogenesis and may be important in understanding the proliferation and enhanced survival of KS tumor cells. Furthermore, the induction of apoptosis in KS tumor cells by GSI and LY-411,575, two known Notch inhibitors, suggests that inactivation of Notch may be a therapeutic approach for treating patients suffering from this potentially lifethreatening disease.
Materials and methods
Cell culture
Human dermal microvascular ECs were purchased from Cambrex (Walkersville, MD, USA) and cultured in EGM-2MV on plates coated with EC attachment factor (Cell Systems, Kirkland, WA, USA). KS tumor cells were isolated from primary lesions and characterized as described previously (Foreman et al., 1996) . The cells were plated on tissue culture dishes coated with EC attachment factor and were maintained in RPMI-1640 and 20% fetal bovine serum (FBS) supplemented with 10% Nutridoma HU (Roche Molecular Biochemicals, Indianapolis, IN, USA), 2 mmol/l L-glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin, 50 mg/ml gentamicin, 50 mg/ml EC growth supplement (ICN Biochemicals, Aurora, OH, USA), and 16 U/ml heparin. SLK cells, a KSHVnegative immortalized KS cell line originally isolated from the oral mucosa of an HIV-negative patient, were maintained in RPMI-1640 containing 10% FBS, 2 mmol/l L-glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin, and 50 mg/ml gentamicin (Herndier et al., 1994) .
Immunostaining
Formalin-fixed, paraffin-embedded tissue sections (5 mm thick) were dewaxed in xylene and ethanol, rehydrated, and briefly microwaved in 0.01 mol/l citrate buffer, pH 6.0, to optimize antigen retrieval. Alternatively, frozen sections or tissue culture cells grown on LabTek Slide Systems (Nalge Nunc International, Naperville, IL, USA) were fixed in ice-cold acetone. Sections were then immunostained to detect Notch receptors, ligands, or target proteins using a highly sensitive avidin-biotin immunoperoxidase technique (Vectastain ABC kit, Vector Laboratories, Burlingame, CA, USA) as described. Antibodies used in this study were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA), unless otherwise noted, and include: Notch-1, Notch-2, Notch-4, Hes-1, Hey1 (HRT1), CD3 (Becton-Dickinson, San Jose, CA, USA), Ki67 (DakoCytomation, Carpinteria, CA, USA), and caspase-3 (R&D Systems, Minneapolis, MN, USA). For detection of apoptosis, TUNEL staining was performed using the ApoTag Peroxidase In Situ Apoptosis detection kit (Serologics Corporation, Norcross, GA, USA) following the manufacturer's instructions. Frozen KS tissue specimens were generously provided by the AIDS and Cancer Specimen Resource, sponsored by the National Cancer Institute, and evaluated by a dermatopathologist (BJN).
Western blot analysis
Whole-cell extracts were prepared by lysing cells in CHAPS buffer containing a mixture of protease inhibitors (MiniComplete, Roche Molecular Biochemicals), incubating the cells for 20 min on ice and centrifuging to remove insoluble cellular debris (Tang et al., 2003) . Protein concentration was determined using a Bradford Assay (Bio-Rad Laboratories, Hercules, CA, USA). Protein (50-100 mg) was loaded onto SDS-polyacrylamide gels, transferred to an Immobilon-P (polyvinylidene difluoride) membrane, and blocked with 5% powdered milk in TBST (50 mM Tris, pH 7.5, 150 mM NaCl, 0.01% Tween-20). The membrane was then incubated with primary antibodies diluted in 2.5% powdered milk in TBST, washed extensively, and incubated with HRP-conjugated species-specific secondary antibodies (Amersham Biosciences, Piscataway, NJ, USA). Proteins were visualized with ECL reagents (Amersham Biosciences) according to the manufacturer's instructions. Even loading of proteins was confirmed by Ponceau S staining and detection of the housekeeping protein, actin, on each blot. The antibodies against Notch1 (bTan20) and Notch2 (C651.6DbHN) developed by Dr S Artavanis-Tsakonas were obtained from the Developmental Studies Hybridoma Bank developed under the auspices of the NICHD and maintained by the University of Iowa (Iowa City, IA, USA). These antibodies recognize the least conserved portions of the intracellular domains of Notch-1 (nucleotides: 6658-7131) and Notch-2 (6508-6906) (Zagouras et al., 1995) . Antibodies for all other Notch pathway proteins were purchased from Santa Cruz Biotechnologies and actin antibodies were obtained from ICN Biomedicals Inc. (Aurora, OH, USA). Differences in protein expression were determined by densitometry analysis using Scion Image Software (Scion Corporation, Frederick, MD, USA). Western blot experiments were repeated at least twice to confirm the results.
Plasmids and transfections
The Hey1 (also known as HesR1, HERP2, HRT1) luciferase reporter construct was the kind gift of Dr M Gessler (University of Wuerzburg, Wuerzburg, Germany). In this construct, approximately 3 kb of the presumed promoter region (À2839 to þ 87) of Hey1 was inserted in front of the luciferase gene in the promoterless vector pLuc. The Hey2 (also known as HesR2, HERP1, HRT2) luciferase reporter construct, containing 1 kb of the Hey2 promoter region inserted upstream of the luciferase gene in the pGL2 basic vector (Promega, Madison, WI, USA), was generously provided by Dr L Kedes (University of Southern California, Los Angeles, CA, USA). The Hes-1A/B luciferase reporter construct, containing the À194 to þ 160 promoter fragment of the Hes-1 gene inserted upstream of the luciferase gene in pGL2, was the gift of Dr S Siodia (University of Chicago, Chicago, IL, USA). Cells were transfected using Cytopure transfection reagent (Qbiogene, Carlsbad, CA, USA) following the manufacturer's instructions.
Luciferase assays
Cells from a transfected 60 mm dish were lifted with trypsin, washed, and resuspended in 150 ml of phosphate-buffered saline. Bright-N-Glo luciferase reagent (150 ml) (Promega) was added with thorough mixing following the manufacturer's instructions. The sample was incubated for 2 min at room temperature and the luciferase activity measured using an FB15 luminometer. The number of cells present in each sample was also counted to normalize the luciferase activity with the total number of cells (Lu et al., 2002) . Owing to significant problems with promoter competition in these experiments, we were unable to cotransfect the cells with a vector to standardize transfection efficiency. As an alternative, we transfected control cells with a plasmid expressing green fluorescent protein (GFP) in each experiment. The percentage of transfected cells was determined by flow cytometry and the average value used to normalize the data for transfection efficiency (data not shown). Under these experimental conditions, we found that transfection efficiencies varied substantially between the different cell types, but reproducibility in replicate experiments within a particular cell type were acceptable. GFP positivity averaged 35.274.2 for ECs, 9.171.7 for KS tumor cells, and 19.074.4 for SLK cells across a minimum of three independent experiments each performed in triplicate.
Inhibition of Notch activation
Cells were treated with increasing concentrations of various GSIs to inhibit Notch activation. As g-secretase is involved in the activation of all four Notch receptors, GSIs are considered nonselective or pan-Notch inhibitors. Our preliminary studies demonstrated that GSI-I (Z-Leu-Leu-Nle-CHO (Nle ¼ Norleucine); EMD Biosciences, San Diego, CA, USA) used at 5-10 mM was the most effective GSI under our experimental conditions. Direct evidence has been previously reported that GSI blocks Notch-1 and Notch-4 cleavage in vitro. The results were confirmed using a pharmacologically distinct g-secretase inhibitor, LY-411,575, known to block Notch activation (Lanz et al., 2004; Wong et al., 2004) .
Detection of apoptosis
DNA/PI staining was performed using standard methodologies. Briefly, 1 Â 10 6 cells were permeabilized with 100% ethanol in the presence of 15% FBS. The cells were washed and then treated for 15 min at 371C with 10 mg/ml RNAse. PI (5 mg/ml) was added, and the cells incubated for 1 h at 41C prior to analysis by flow cytometry using a Coulter Epics MCL flow cytometer with 10 000 cells analysed per gated determination. The results were confirmed using the Immunotech Annexin V staining kit following the manufacturers' instructions. At least three independent experiments were performed showing similar results.
Proliferation assay
Cell proliferation was quantitated using a WST-1 assay, a highly sensitive, colorimetric alternative to 3 H-thymidine incorporation assays. Briefly, 4 Â 10 4 cells/well were plated in a 96-well plate and allowed to proliferate overnight. The cells were then treated with GSI or DMSO as a control, and after 24 h, 10 ml of WST-1 reagent (Roche Applied Science) was added per well. After an additional 4 h incubation, the plate was shaken thoroughly for 1 min, and color development measured on a microplate reader at 450 nm.
Nude mouse model
Nude mice were injected with 2-3 Â 10 6 SLK cells intradermally in the rear flank, and palpable tumors formed in 4-6 days. On the seventh day, the established tumors were directly injected with GSI (resuspended in DMSO and diluted in sterile saline; 48 mg/dose), DMSO (diluted in sterile saline), or were left untreated as a control. Injections continued every other day for a week and tumor dimensions were measured and recorded at each injection. Following treatment, the animals were killed and the tumors measured, photographed, and excised for histology and immunostaining. Unexpectedly, GSI injection resulted in a pain/distress response by the animals, which was completely alleviated by 0.1 mg/kg buprenorphine. Therefore, all animals were given buprenorphine 15 min prior to administering the GSI or DMSO control. Comparison of data with and without buprenorphine revealed no differences. All animal experiments were performed following institutional guidelines in accordance with the US Public Health Service Policy on Humane Care and Use of Laboratory Animals, and approval of the Loyola IACUC committee.
